ArticleBiology direct2026
METTL1 facilitates colorectal cancer progression through internal m7G methylation of MACC1 and SDCCAG8 mRNA.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
N7-Methylguanosine (m7G) modification, as one of main types of RNA modification, has been implicated in several cancers. However, its function and regulatory mechanism in colorectal cancer (CRC) progression remain poorly understood. In this study, we found methyltransferase-like protein-1 (METTL1), the key m7G methyltransferase, is highly expressed in CRC tissues via whole-transcriptome sequencing, qRT-PCR and immunohistochemical analysis. Functional investigations revealed that METTL1 promotes CRC growth and proliferation both in vitro and in vivo, which depends on its m7G methyltransferase activity. Through m7G-MeRIP-sequencing and high-throughput mRNA sequencing, metastasis-associated in colon cancer 1 (MACC1) and serologically defined colon cancer antigen 8 (SDCCAG8) were identified as new targets of METTL1-mediated internal m7G modification. Further explorations confirmed that METTL1 regulates expression of the two genes by enhancing their mRNA stabilities. Overexpression of MACC1 or SDCCAG8 could rescue those phenotypic defects induced by METTL1 knockdown. Additionally, METTL1 expression is closely related to MACC1 or SDCCAG8 expression in CRC clinical samples. Collectively, these findings unveil that METTL1 facilitates CRC progression by regulating MACC1 and SDCCAG8 in an m7G-dependent manner, highlighting that METTL1 could be a potential therapeutic target in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.